查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1338907

出血性疾病市場、份額、規模、趨勢、行業分析報告：按類型；按藥物類別；按地區；按細分市場預測，2023-2032 年

Bleeding Disorders Market Share, Size, Trends, Industry Analysis Report, By Type (Hemophilia A, Hemophilia B, Von Willebrand Diseases); By Drug Class; By Region; Segment Forecast, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 119 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的最新研究，到 2032 年，全球出血性疾病市場規模預計將達到 274.9 億美元。 該報告提供了對當前市場動態的詳細見解，並對未來市場成長進行了分析。

最常見的血友病類型是血友病 A，當凝血因子 8 不足時就會發生這種疾病。 根據美國疾病管制與預防中心 (CDC) 的數據，美國每 10 萬人中就有 10 人患有 A 型血友病。 凝血因子 9 缺乏會導致 B 型血友病。 根據疾病預防控制中心 (CDC) 的數據，B 型血友病影響著約十分之三的美國人。 這將推動未來幾年出血性疾病市場的成長和需求。

A 型血友病患病率的增加、對該疾病的認識和篩檢的提高、新療法的進步以及該疾病患者預期壽命的延長都在推動出血性疾病市場的增長。Masu。 據 Statista 稱，2021 年，A 型血友病將影響全球 185,318 人，另有 17,951 人受到各種血小板疾病的影響。 隨著越來越多的患者被診斷出患有 A 型和 B 型血友病，對凝血因子替代療法的需求不斷增加，推動了市場的成長。

諸如血友病和馮維勒布蘭德病等出血性疾病的特徵是血液中凝血因子的缺乏或功能障礙。 患有出血性疾病的患者需要定期輸注凝血因子替代療法以預防或控制出血事件。 這些凝血因子主要來自捐贈的血液或血漿。 為了產生這些凝血因子，必須有捐贈者血液和血漿。

出血性疾病的盛行率不斷增加，增加了對捐血和凝血因子替代治療的需求。 根據世界衛生組織（WHO）統計，2008年至2018年，119個國家的自願無償捐血增加了1,070萬人次。 這可能為出血性疾病市場的成長提供廣泛的機會。

B型肝炎每年導致 60 萬至 120 萬人死亡，15% 至 40% 的感染患者會發展為致命的肝病（肝硬化、肝衰竭、肝細胞癌）。 肝硬化或肝細胞癌患者發生出血性疾病的風險增加，因為肝臟產生的凝血因子減少。 因此，這些患者對凝血因子替代療法的需求量很大，推動了市場成長。

出血性疾病市場報告重點

由於甲型血友病患病率不斷增加以及對新療法的需求不斷增加，預計甲型血友病將會成長。

由於預防需求的增加和製造技術的進步，重組凝血因子濃縮物實現了高成長率。

由於出血性疾病的盛行率不斷增加以及研發投資的增加，預計亞太地區將出現強勁的成長率。

目錄

第1章簡介

第 2 章執行摘要

第3章研究方法

第 4 章全球出血性疾病市場洞察

  • 出血性疾病市場 - 產業概況
  • 出血性疾病的市場動態
    • 推動者和機會
      • 血友病患病率不斷上升
      • 新興國家對出血性疾病的認識不斷提高
    • 抑制因素和挑戰
      • 出血性疾病的治療費用很高
  • 杵分析
  • 出血性疾病的產業趨勢
  • 價值鏈分析
  • COVID-19 感染的影響分析

第5章全球出血性疾病市場，依類型

  • 主要發現
  • 簡介
  • 甲型血友病
  • B型血友病
  • 血管性血友病

第 6 章全球出血性疾病市場（依藥物類別）

  • 主要發現
  • 簡介
  • 血漿衍生凝血因子濃縮物
  • 重組凝血因子
  • 去氨加壓素
  • 抗纖溶藥物
  • 纖維蛋白密封劑

第 7 章全球出血性疾病市場（按地區）

  • 主要發現
  • 簡介
    • 2019-2032 年各地區出血性疾病市場評估
  • 出血性疾病市場 - 北美
    • 北美：出血性疾病市場，依藥物類別，2019-2032 年
    • 北美：2019-2032 年出血性疾病市場（依類型）
    • 出血性疾病市場 - 美國
    • 出血性疾病市場 - 加拿大
  • 出血性疾病市場 - 歐洲
    • 歐洲：出血性疾病市場，依藥物類別，2019-2032 年
    • 歐洲：出血性疾病市場（按類型），2019-2032 年
    • 出血性疾病市場 - 英國
    • 出血性疾病市場 - 法國
    • 出血性疾病市場 - 德國
    • 出血性疾病市場 - 義大利
    • 出血性疾病市場 - 西班牙
    • 出血性疾病市場 - 荷蘭
    • 出血性疾病市場 - 俄羅斯
  • 出血性疾病市場 - 亞太地區
    • 亞太地區：出血性疾病市場（依藥物類別），2019-2032 年
    • 亞太地區：2019-2032 年出血性疾病市場（按類型）
    • 出血性疾病市場 - 中國
    • 出血性疾病市場 - 印度
    • 出血性疾病市場 - 馬來西亞
    • 出血性疾病市場 - 日本
    • 出血性疾病市場 - 印度尼西亞
    • 出血性疾病市場－韓國
  • 出血性疾病市場 - 中東和非洲
    • 中東和非洲：出血性疾病市場（按藥物類別），2019-2032 年
    • 中東和非洲：2019-2032 年出血性疾病市場（按類型）
    • 出血性疾病市場 - 沙烏地阿拉伯
    • 出血性疾病市場 - 阿拉伯聯合大公國
    • 出血性疾病市場 - 以色列
    • 出血性疾病市場 - 南非
  • 出血性疾病市場 - 拉丁美洲
    • 拉丁美洲：出血性疾病市場（依藥物類別），2019-2032 年
    • 拉丁美洲：2019-2032 年出血性疾病市場（按類型）
    • 出血性疾病市場 - 墨西哥
    • 出血性疾病市場 - 巴西
    • 出血性疾病市場 - 阿根廷

第8章競爭態勢

  • 擴張與收購分析
    • 放大
    • 收購
  • 夥伴關係/協作/協議/揭露

第9章公司簡介

  • Novo Nordisk
  • Bayer
  • Baxter
  • Alnylam Pharmaceuticals
  • Xenetic Biosciences
  • Bristol-Myers
  • Sanofi
  • Amgen
  • Janssen
  • Bioverativ Inc
Product Code: PM3351

The global bleeding disorders market size is expected to reach USD 27.49 billion by 2032, according to a new study by Polaris Market Research. The report "Bleeding Disorders Market Share, Size, Trends, Industry Analysis Report, By Type (Hemophilia A, Hemophilia B, Von Willebrand Diseases); By Drug Class; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The most prevalent kind of hemophilia is hemophilia A. It occurs when there is insufficient clotting factor 8. According to the Centres for Disease Control and Prevention (CDC), hemophilia A affects roughly 10 in every 100,000 persons in the United States. When clotting factor 9 levels are insufficient, hemophilia B develops. According to the CDC, hemophilia B affects roughly 3 in 100,000 Americans. This is driving the growth and demand for the bleeding disorders market in coming years.

The increasing prevalence of hemophilia A, greater awareness and screening for the disease, advances in new therapies, and the longer life expectancy of patients with the disease are all contributing factors to the growth of the bleeding disorders market. According to Statista, Hemophilia A affected 185,318 persons globally in 2021, while another 17,951 people had various platelet diseases. As more patients are diagnosed with hemophilia A and B, the demand for clotting factor replacement therapy increases, which fuels the growth of the market.

Bleeding disorders, such as hemophilia and von Willebrand disease, are characterized by a deficiency or dysfunction of clotting factors in the blood. Patients with bleeding disorders require regular infusions of clotting factor replacement therapy to prevent or control bleeding episodes. These clotting factors are primarily derived from donated blood and plasma. In order to produce these clotting factors, donor blood and plasma must be available.

Due to the rising prevalence of bleeding diseases, there is an increase in need for blood donations as well as clotting factor replacement therapy. According to the World Health Organization, 119 nations have recorded an increase in voluntary unpaid blood donations of 10.7 million from 2008 to 2018. This will create a wide range of opportunities for the growth of the bleeding disorders market.

HBV causes 600,000 to 1.2 million fatalities annually, with 15-40% of infected patients developing fatal liver conditions (cirrhosis, liver failure, and hepatocellular carcinoma). Patients with liver cirrhosis and HCC are at an increased risk of developing bleeding disorders due to the decreased production of clotting factors by the liver. As a result, the demand for clotting factor replacement therapy is high among these patients, which fuels the growth of the market.

Bleeding Disorders Market Report Highlights

Hemophilia A Type is anticipated to grow due to the increasing prevalence of hemophilia A and rising demand for novel therapies.

Recombinant Coagulation Factor Concentrates segment accounted for the higher growth rate owing to the growing demand for prophylaxis and advancements in manufacturing technology.

Asia Pacific is expected to grow at a significant growth rate owing to the increasing prevalence of bleeding disorders and investments in research & development.

The global players include: Novo Nordisk, Bayer, Baxter International, Alnylam Pharmaceuticals, Pfizer, Xenetic Biosciences, Bristol, Sanofi, Amgen, Janssen, and Bioverativ Inc.

Polaris Market Research has segmented the bleeding disorders market report based on type, drug class and region:

Bleeding Disorders, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Diseases

Bleeding Disorders, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • Plasma Derived Coagulation Factor Concentrates
  • Recombinant Derived Coagulation Factor
  • Desmopressin
  • Antifibrinolytics
  • Fibrin Sealants

Bleeding Disorders, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Bleeding Disorders Market Insights

  • 4.1. Bleeding Disorders Market - Industry Snapshot
  • 4.2. Bleeding Disorders Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rise in prevalence of hemophilia
      • 4.2.1.2. Rise in awareness about bleeding disorders in developing countries
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of bleeding disorders treatments
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Bleeding Disorders Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Bleeding Disorders Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Bleeding Disorders, by Type, 2019-2032 (USD Billion)
  • 5.3. Hemophilia A
    • 5.3.1. Global Bleeding Disorders Market, by Hemophilia A, by Region, 2019-2032 (USD Billion)
  • 5.4. Hemophilia B
    • 5.4.1. Global Bleeding Disorders Market, by Hemophilia B, by Region, 2019-2032 (USD Billion)
  • 5.5. Von Willebrand Diseases
    • 5.5.1. Global Bleeding Disorders Market, by Von Willebrand Diseases, by Region, 2019-2032 (USD Billion)

6. Global Bleeding Disorders Market, by Drug Class

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • 6.3. Plasma Derived Coagulation Factor Concentrates
    • 6.3.1. Global Bleeding Disorders Market, by Plasma Derived Coagulation Factor Concentrates, by Region, 2019-2032 (USD Billion)
  • 6.4. Recombinant Derived Coagulation Factor
    • 6.4.1. Global Bleeding Disorders Market, by Recombinant Derived Coagulation Factor, by Region, 2019-2032 (USD Billion)
  • 6.5. Desmopressin
    • 6.5.1. Global Bleeding Disorders Market, by Electric, by Region, 2019-2032 (USD Billion)
  • 6.6. Antifibrinolytics
    • 6.6.1. Global Bleeding Disorders Market, by Antifibrinolytics, by Region, 2019-2032 (USD Billion)
  • 6.7. Fibrin Sealants
    • 6.7.1. Global Bleeding Disorders Market, by Fibrin Sealants, by Region, 2019-2032 (USD Billion)

7. Global Bleeding Disorders Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Bleeding Disorders Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Bleeding Disorders Market - North America
    • 7.3.1. North America: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.3.2. North America: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.3.3. Bleeding Disorders Market - U.S.
      • 7.3.3.1. U.S.: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.3.4. Bleeding Disorders Market - Canada
      • 7.3.4.1. Canada: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • 7.4. Bleeding Disorders Market - Europe
    • 7.4.1. Europe: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.4.3. Bleeding Disorders Market - UK
      • 7.4.3.1. UK: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.4.4. Bleeding Disorders Market - France
      • 7.4.4.1. France: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.4.5. Bleeding Disorders Market - Germany
      • 7.4.5.1. Germany: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.4.6. Bleeding Disorders Market - Italy
      • 7.4.6.1. Italy: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.4.7. Bleeding Disorders Market - Spain
      • 7.4.7.1. Spain: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.4.8. Bleeding Disorders Market - Netherlands
      • 7.4.8.1. Netherlands: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.4.9. Bleeding Disorders Market - Russia
      • 7.4.9.1. Russia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • 7.5. Bleeding Disorders Market - Asia Pacific
    • 7.5.1. Asia Pacific: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.5.3. Bleeding Disorders Market - China
      • 7.5.3.1. China: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.5.4. Bleeding Disorders Market - India
      • 7.5.4.1. India: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.5.5. Bleeding Disorders Market - Malaysia
      • 7.5.5.1. Malaysia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.5.6. Bleeding Disorders Market - Japan
      • 7.5.6.1. Japan: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.5.7. Bleeding Disorders Market - Indonesia
      • 7.5.7.1. Indonesia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.5.8. Bleeding Disorders Market - South Korea
      • 7.5.8.1. South Korea: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • 7.6. Bleeding Disorders Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.6.3. Bleeding Disorders Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.6.4. Bleeding Disorders Market - UAE
      • 7.6.4.1. UAE: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.6.5. Bleeding Disorders Market - Israel
      • 7.6.5.1. Israel: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.6.6. Bleeding Disorders Market - South Africa
      • 7.6.6.1. South Africa: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • 7.7. Bleeding Disorders Market - Latin America
    • 7.7.1. Latin America: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.7.3. Bleeding Disorders Market - Mexico
      • 7.7.3.1. Mexico: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.7.4. Bleeding Disorders Market - Brazil
      • 7.7.4.1. Brazil: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.7.5. Bleeding Disorders Market - Argentina
      • 7.7.5.1. Argentina: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Novo Nordisk
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Bayer
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Baxter
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Alnylam Pharmaceuticals
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Xenetic Biosciences
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Bristol-Myers
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Sanofi
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Amgen
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Janssen
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Bioverativ Inc
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development

List of Tables

  • Table 1 Global Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 2 Global Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 3 Bleeding Disorders Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 5 North America: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 6 U.S.: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 7 U.S.: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 8 Canada: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 9 Canada: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 10 Europe: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 11 Europe: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 12 UK: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 13 UK: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 14 France: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 15 France: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 16 Germany: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 17 Germany: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 18 Italy: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 19 Italy: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 20 Spain: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 21 Spain: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Russia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 25 Russia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 28 China: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 29 China: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 30 India: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 31 India: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 34 Japan: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 35 Japan: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 38 South Korea: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 39 South Korea: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 44 UAE: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 45 UAE: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 46 Israel: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 47 Israel: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 48 South Africa: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 49 South Africa: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 50 Latin America: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 51 Latin America: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 52 Mexico: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 53 Mexico: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Brazil: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 55 Brazil: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 56 Argentina: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 57 Argentina: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Bleeding Disorders Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Drug Class
  • Figure 7 Global Bleeding Disorders Market, by Drug Class, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Type
  • Figure 9 Global Bleeding Disorders Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 10 Bleeding Disorders Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Bleeding Disorders Market